文献

J-GLOBAL ID：202002262366068986   整理番号：20A0880017

HIVの治癒:標的と明確な持続感染の探索【JST・京大機械翻訳】

Curing HIV: Seeking to Target and Clear Persistent Infection

著者 (28件)： Margolis David M. (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Margolis David M. (Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Margolis David M. (Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Margolis David M. (Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, Chapel Hill, NC 27599, USA) ,  Archin Nancie M. (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Archin Nancie M. (Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Cohen Myron S. (Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Cohen Myron S. (Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA) ,  Eron Joseph J. (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Eron Joseph J. (Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Ferrari Guido (Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA) ,  Garcia J. Victor (International Center for the Advancement of Translational Science, Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Garcia J. Victor (Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Gay Cynthia L. (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Gay Cynthia L. (Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Goonetilleke Nilu (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Goonetilleke Nilu (Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Joseph Sarah B. (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Joseph Sarah B. (Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Joseph Sarah B. (Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Joseph Sarah B. (Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA) ,  Swanstrom Ronald (Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Swanstrom Ronald (Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA) ,  Swanstrom Ronald (Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Turner Anne-Marie W. (UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Turner Anne-Marie W. (Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Wahl Angela (International Center for the Advancement of Translational Science, Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA) ,  Wahl Angela (Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA)
資料名： Cell (Cambridge, Mass.)  (Cell (Cambridge, Mass.))
巻： 181  号： 1  ページ： 189-206  発行年： 2020年 
JST資料番号： A0707B  ISSN： 0092-8674  資料種別： 逐次刊行物 (A)
記事区分： 文献レビュー  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： ヒト免疫不全ウイルス1型(HIV-1)感染は抗レトロウイルス療法(ART)の年にもかかわらず持続する。慢性感染の柱頭と負担を除去するために,HIV感染を根絶または治療するアプローチが望まれている。ウイルス潜伏を逆転させる治療によりARTを増強する試みは,明らかな感染に対する免疫療法と対になっているが,臨床に進歩しているが,その分野はまだ幼児期にある。基礎研究をレビューし,HIV治癒研究における新しい洞察を強調した。ARTデリバリーとHIV予防戦略の進歩と共に,HIV感染を明らかにする将来の治療は,HIVパンデミックのり患の社会を緩和する可能性がある。Copyright 2020 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 柱頭 ,  *HIV【ウイルス】 ,  HIV感染症 ,  HIV1 ,  *持続感染 ,  免疫療法 ,  予防
準シソーラス用語： ウイルス潜伏 ,  高活性抗レトロウイルス療法 , 【Automatic Indexing@JST】

分類 (2件)： 感染症・寄生虫症一般  (GD01010H) ,  ウイルス感染の生理と病原性  (EG04042Y)

タイトルに関連する用語 (5件)： HIV ,  治癒 ,  標的 ,  持続感染 ,  探索